The Progeria Research Foundation Research Grants

The Progeria Research Foundation has brought Progeria to the forefront of research efforts, engaging large, reputable institutions such as the National Institutes of Health (NIH) and Children’s Hospital Boston (CHB) to invest their resources in Hutchinson-Gilford Progeria Syndrome. In addition, NIH has co-sponsored  8 scientific workshops with PRF, and CHB is a partner in the Progeria Clinical Drug Trials.

In our continuing effort to encourage researchers to work in this field, we solicit proposals worldwide and through our scientific workshops. Grants are considered twice per year, usually at the Board of Directors’ June and December meetings, with applications due approximately twelve weeks prior.

 RFP Listing for PRF Grants – Fall 2017

September 2017: PRF encourages proposals in the areas listed below. Investigators are not limited to applications that address these priorities, but rather are encouraged to use them to better understand the needs of the field at this time.

PRF is seeking proposals that address the following priorities:

1. Discovery of biological markers of disease in HGPS that can be assessed in human and/or mouse samples. Highest priority will be given to those markers that can be assayed in easily obtainable human samples such as blood, urine, and cheek swabs. In addition, proposals that explore biomarker relevance to disease process and /or change in markers with disease treatment are encouraged.
2. Discovery and/or testing of candidate treatment compounds in both cell based and mouse models of HGPS. Of note, proposals should test compounds in a progerin-producing mouse model as the priority. Comparisons to other mouse models of disease, such as ZMPSTE24 -/- and other non-progerin producing mouse models are acceptable, but only as a comparison to progerin-producing models.

For more information, please visit: https://www.progeriaresearch.org/research-funding-opportunities/